ReviewAmerican journal of clinical dermatology2026
Skin Cancer in Solid Organ Transplant Recipients: A Review.
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Posttransplant Malignant Neoplasms in Solid Organ Transplant Recipients.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid organ transplant recipients (SOTRs) experience a significantly elevated risk of skin cancer, primarily due to the immunosuppressive and carcinogenic effects of anti-rejection medications. Both incidence and mortality are substantially higher than in the general population, necessitating a tailored approach to prevention, surveillance and management. This comprehensive review synthesises the field of transplant dermatology and highlights key advancements. Recent epidemiological studies are explored, comparing incidence rates with those in the general population and other immunosuppressed groups. We also review the significance of risk factors, including those shared with the general population and those unique to SOTRs. Current prevention strategies are discussed, with a focus on the evidence behind chemoprophylactic agents. We also summarise current guidelines regarding screening and management of skin cancer in SOTRs. While the general approach to skin cancer in SOTRs has remained similar over the past decades, a broad range of consensus statements are now available, providing clearer guidance for clinicians managing these high-risk patients.
Indexed as
Identifiers
41764150What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.